Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 1, 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the Company's issued share capital as of November 30, 2016:
- Total Issued Ordinary Shares: 5,367,734,859 (25 pence each).
- Treasury Shares: 491,505,950.
- Total Voting Rights: 4,876,228,909.
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document's sole purpose is to establish the denominator for shareholder interest calculations under the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,876,228,909) against the latest 20-F annual report.
- Confirm the number of shares held in Treasury (491,505,950) to ensure accurate calculation of beneficial ownership thresholds.
- Check subsequent filings for any changes in share capital or treasury holdings since November 30, 2016.